Journal article icon

Journal article

Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care.

Abstract:

This study compared the cost-effectiveness of meropenem with that of imipenem plus cilastatin in the treatment of severe infections in hospital intensive care in the UK. A Markov model was constructed to model lifetime costs and quality-adjusted life years (QALYs) of using meropenem and imipenem plus cilastatin for the treatment of severe infections in intensive care. Estimates of effectiveness, utility weights and costs were obtained from the published literature. Probabilistic sensitivity a...

Expand abstract

Actions


Access Document


Publisher copy:
10.1007/s10198-005-0333-y

Authors


Edwards, SJ More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Population Health
Journal:
The European journal of health economics : HEPAC : health economics in prevention and care
Volume:
7
Issue:
1
Pages:
72-78
Publication date:
2006-03-05
DOI:
EISSN:
1618-7601
ISSN:
1618-7598
URN:
uuid:d90640a3-999d-48be-8359-2dd7f2b86c46
Source identifiers:
163035
Local pid:
pubs:163035

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP